author-photo

Katherine Sue Robinson

Dalhousie University

12

Papers

85

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Discrepant platelet and plasma von Willebrand factor in von Willebrand disease patients with p.Pro2808Leufs*24

2017 Journal of Thrombosis and Haemostasis
Show All
- Source
- Cite
- Save
Citations (5)
Long‐term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non‐Hodgkin lymphoma

2017 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (18)
Long-Term Outcomes, Secondary Malignancies, and Stem Cell Collection Following Bendamustine in Patients with Previously Treated Indolent Non-Hodgkin Lymphoma

2015 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Type 3 Von Willebrand Disease: Plasma Versus Platelets.

2009 Blood
Show All
- Source
- Cite
- Save
Citations (1)
Phase II Results of Bendamustine in Combination with Rituximab in Relapsed Indolent and Mantle-Cell Non-Hodgkin’s Lymphoma.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (7)
The Effect of Dalteparin on Coagulation Activation during Pregnancy in Women with Thrombophilia: A Randomised Trial.

2006 Blood
Show All
- Source
- Cite
- Save
Citations (2)
A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin’s lymphoma (NHL)

2006 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (21)
Bendamustine HCl (TREANDA TM ) Treatment in Combination with Rituximab Results in Objective Responses in Patients with Refractory/Relapsed Indolent B-Cell and Mantle Cell Non-Hodgkin’s Lymphoma: Results from Phase II Multicenter Study (SDX-105-02).

2005 Blood
Show All
- Source
- Cite
- Save
Citations (7)
The novel alkylator bendamustine HCl is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity

2005 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (9)